Your browser is no longer supported. Please, upgrade your browser.
Settings
SYRS Syros Pharmaceuticals, Inc. daily Stock Chart
SYRS [NASD]
Syros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.65 Insider Own0.70% Shs Outstand45.78M Perf Week1.33%
Market Cap356.16M Forward P/E- EPS next Y-1.78 Insider Trans-54.42% Shs Float42.64M Perf Month19.94%
Income-73.60M PEG- EPS next Q-0.42 Inst Own92.90% Short Float10.89% Perf Quarter-41.56%
Sales9.90M P/S35.98 EPS this Y1.70% Inst Trans5.03% Short Ratio10.10 Perf Half Y-15.52%
Book/sh1.00 P/B8.00 EPS next Y-10.60% ROA-49.70% Target Price- Perf Year66.32%
Cash/sh2.09 P/C3.83 EPS next 5Y- ROE-111.50% 52W Range4.26 - 14.69 Perf YTD15.77%
Dividend- P/FCF- EPS past 5Y-22.20% ROI-97.20% 52W High-47.24% Beta1.90
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin- 52W Low81.92% ATR0.58
Employees83 Current Ratio3.50 Sales Q/Q533.30% Oper. Margin- RSI (14)43.49 Volatility5.67% 7.89%
OptionableYes Debt/Eq0.44 EPS Q/Q8.70% Profit Margin- Rel Volume0.75 Prev Close8.00
ShortableYes LT Debt/Eq0.44 EarningsNov 05 AMC Payout- Avg Volume460.04K Price7.75
Recom2.00 SMA20-5.58% SMA50-7.07% SMA200-14.86% Volume184,481 Change-3.13%
Nov-04-20Upgrade H.C. Wainwright Neutral → Buy $11 → $15
Sep-22-20Initiated Alliance Global Partners Buy $18
Jan-17-20Downgrade Wedbush Outperform → Neutral
Mar-08-19Resumed JMP Securities Mkt Outperform $18
Feb-14-19Resumed Oppenheimer Outperform $13
Nov-05-18Upgrade ROTH Capital Neutral → Buy
Mar-13-18Reiterated Wedbush Outperform $11 → $13
Oct-31-17Resumed Piper Jaffray Overweight $30
Oct-23-17Initiated ROTH Capital Neutral $15
Aug-10-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Nov-16-20 08:00AM  
Nov-09-20 10:09AM  
Nov-05-20 04:01PM  
02:30PM  
Nov-04-20 10:26AM  
10:12AM  
Oct-29-20 08:30AM  
Oct-27-20 01:14PM  
Oct-24-20 07:30AM  
Oct-15-20 01:38PM  
Oct-09-20 07:30AM  
Sep-10-20 02:47PM  
08:30AM  
Sep-09-20 08:31AM  
Aug-19-20 08:32AM  
Aug-06-20 09:55AM  
07:31AM  
Aug-05-20 09:09AM  
Jul-30-20 12:34PM  
08:30AM  
Jul-07-20 08:00AM  
Jul-05-20 02:45PM  
Jun-17-20 08:00AM  
Jun-15-20 06:31AM  
Jun-11-20 08:31AM  
May-29-20 08:01AM  
May-28-20 08:00AM  
May-19-20 07:22AM  
May-13-20 05:01PM  
May-12-20 10:32AM  
May-08-20 02:31PM  
May-07-20 10:05AM  
08:08AM  
07:30AM  
May-06-20 10:01AM  
Apr-30-20 08:30AM  
Apr-29-20 12:34PM  
Apr-07-20 09:30AM  
Mar-26-20 10:16AM  
Mar-22-20 10:27AM  
Mar-05-20 08:45AM  
07:30AM  
Feb-27-20 12:30PM  
08:00AM  
Feb-24-20 08:00AM  
Feb-13-20 08:00AM  
Feb-06-20 02:03PM  
Jan-29-20 08:31AM  
Jan-28-20 08:31AM  
Jan-15-20 08:29AM  
Jan-12-20 09:00AM  
Dec-20-19 11:40AM  
08:01AM  
Dec-19-19 05:20PM  
08:00AM  
Dec-18-19 07:51AM  
07:15AM  
07:00AM  
Dec-16-19 07:35AM  
Dec-08-19 08:00AM  
Dec-03-19 11:44PM  
Dec-02-19 01:50PM  
Nov-26-19 08:31AM  
08:31AM  
Nov-19-19 07:01AM  
Nov-12-19 09:25AM  
08:00AM  
Nov-06-19 06:09PM  
09:01AM  
Nov-05-19 08:30AM  
Oct-31-19 10:34AM  
Oct-29-19 04:01PM  
Oct-25-19 08:47AM  
Oct-24-19 08:31AM  
Oct-17-19 07:00AM  
Sep-20-19 02:55PM  
Sep-13-19 10:24AM  
Aug-27-19 01:59AM  
Aug-06-19 04:01PM  
Aug-02-19 10:24PM  
Aug-01-19 09:05AM  
Jul-25-19 08:30AM  
Jun-27-19 07:25AM  
07:23AM  
Jun-12-19 08:31AM  
08:01AM  
May-07-19 08:31AM  
May-06-19 09:17AM  
May-02-19 07:59AM  
May-01-19 11:24PM  
08:55AM  
07:30AM  
Apr-24-19 08:01AM  
Apr-17-19 08:01AM  
Apr-09-19 04:01PM  
Apr-05-19 01:41PM  
07:48AM  
07:15AM  
Apr-04-19 04:18PM  
Apr-02-19 04:01PM  
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young Richard ADirectorNov 17Sale8.755,35746,874339,211Nov 18 04:33 PM
Young Richard ADirectorNov 16Sale8.986335,684344,568Nov 18 04:33 PM
Young Richard ADirectorOct 19Sale8.755,67349,639335,201Oct 19 06:36 PM
Young Richard ADirectorOct 15Sale8.753172,774340,874Oct 16 04:39 PM
Young Richard ADirectorSep 15Sale10.395,99062,236341,191Sep 16 08:32 AM
Olson Eric RChief Scientific OfficerAug 18Option Exercise1.0110,78710,89510,787Aug 19 04:35 PM
Olson Eric RChief Scientific OfficerAug 18Sale13.0010,787140,2310Aug 19 04:35 PM
AKKARAJU SRINIVASDirectorAug 18Sale13.10158,5832,076,7241,274,616Aug 19 04:03 PM
Olson Eric RChief Scientific OfficerAug 17Option Exercise1.014,9635,0134,963Aug 19 04:35 PM
Olson Eric RChief Scientific OfficerAug 17Sale13.004,96364,5190Aug 19 04:35 PM
AKKARAJU SRINIVASDirectorAug 17Sale13.007449,6721,433,199Aug 19 04:03 PM
Young Richard ADirectorAug 17Sale12.595,99075,414347,181Aug 19 04:33 PM
Young Richard ADirectorJul 15Sale11.855,99070,982353,171Jul 17 04:11 PM
Olson Eric RChief Scientific OfficerJul 07Sale11.721,75320,5380Jul 07 07:33 PM
AKKARAJU SRINIVASDirectorJul 01Sale11.014,62750,9661,433,943Jul 06 04:00 PM
AKKARAJU SRINIVASDirectorJun 25Sale11.1554,972612,8501,438,570Jun 25 08:38 PM
AKKARAJU SRINIVASDirectorJun 24Sale11.0748,775539,7881,493,542Jun 25 08:38 PM
AKKARAJU SRINIVASDirectorJun 23Sale11.1150,953565,9301,542,317Jun 25 08:38 PM
Young Richard ADirectorJun 15Sale8.755,99052,413359,161Jun 16 04:53 PM
Young Richard ADirectorMay 15Sale9.225,99055,242365,151May 15 05:13 PM
Alles Mark JDirectorMay 13Buy8.8610,00088,59010,000May 13 05:05 PM
Young Richard ADirectorApr 15Sale8.7523,960209,650371,141Apr 17 04:02 PM
Olson Eric RChief Scientific OfficerFeb 18Sale7.381,44610,6740Feb 20 04:15 PM
Simonian Nancy APresident & CEODec 23Option Exercise3.0452,401159,299533,689Dec 23 04:54 PM